Leadership change at Jazz Pharmaceuticals marks a new chapter

Jazz Pharmaceuticals is ushering in a new era as Renee Gala steps up as president and CEO this August. With three decades of experience spanning finance, strategy, and commercial operations—including stints at Grail, Theravance, and Eli Lilly—Gala brings both depth and momentum to a business navigating complex global healthcare demands.

Her appointment comes at a pivotal moment for the private healthcare sector, as leadership agility becomes a competitive advantage in an increasingly innovation-led environment. Outgoing CEO and co-founder Bruce Cozadd will remain as chairperson of the board, supporting continuity as the company sharpens its commercial and R&D focus under Gala’s leadership.

Want more on the transition and what it could mean for healthcare’s next wave? Explore the full story here.